Literature DB >> 33175216

The impact of pre-analytical parameters on class II biomarkers by immunohistochemistry: concordance across four tissue processing protocols.

Bin Xu1, Samira Alminawi2, Patrice Boulianne2, Yan Ming Shang2, Michelle R Downes2, Elzbieta Slodkowska3.   

Abstract

In the modern era of precision medicine, a number of class II immunohistochemistry (IHC) biomarkers are routinely tested in pathologic laboratories to select cancer patients who may be candidates for hormonal, targeted, and immune therapies. Pre-analytical factors, including tissue processing, are critical components of biomarker testing and require validation to ensure reliable results. In this study, we aimed to study the impact of tissue processing on biomarkers (including ER, PR, HER2, mismatch repair (MMR) proteins, BRAF V600E, and PD-L1) in a large prospective cohort of 109 tumors. We found that ER and MMR were not impacted; PR, HER2, and BRAF V600E were minimally affected; and PD-L1 regardless of the antibody clone was strongly influenced by a combination of tissue processing procedures and intratumoral heterogeneity. Our findings suggest that validation of pre-analytical parameters, such as tissue processing, is important for certain class II biomarkers, in particular PD-L1 IHC.

Entities:  

Keywords:  Class II biomarkers; ER; Immunohistochemistry; PD-L1; Pre-analytical

Mesh：

Substances：

Year:  2020        PMID： 33175216     DOI： 10.1007/s00428-020-02960-z

Source DB:  PubMed          Journal:  Virchows Arch        ISSN： 0945-6317            Impact factor:   4.064


  23 in total

Review 1.  PD-L1 Testing for Lung Cancer in 2019: Perspective From the IASLC Pathology Committee.

Authors:  Sylvie Lantuejoul; Ming Sound-Tsao; Wendy A Cooper; Nicolas Girard; Fred R Hirsch; Anja C Roden; Fernando Lopez-Rios; Deepali Jain; Teh-Ying Chou; Noriko Motoi; Keith M Kerr; Yasushi Yatabe; Elisabeth Brambilla; John Longshore; Mauro Papotti; Lynette M Sholl; Erik Thunnissen; Natasha Rekhtman; Alain Borczuk; Lukas Bubendorf; Yuko Minami; Mary Beth Beasley; Johan Botling; Gang Chen; Jin-Haeng Chung; Sanja Dacic; David Hwang; Dongmei Lin; Andre Moreira; Andrew G Nicholson; Masayuki Noguchi; Giuseppe Pelosi; Claudia Poleri; William Travis; Akihiko Yoshida; Jillian B Daigneault; Ignacio I Wistuba; Mari Mino-Kenudson
Journal:  J Thorac Oncol       Date:  2019-12-20       Impact factor: 15.609

2.  Evolution of Quality Assurance for Clinical Immunohistochemistry in the Era of Precision Medicine: Part 1: Fit-for-Purpose Approach to Classification of Clinical Immunohistochemistry Biomarkers.

Authors:  Carol C Cheung; Corrado D'Arrigo; Manfred Dietel; Glenn D Francis; C Blake Gilks; Jacqueline A Hall; Jason L Hornick; Merdol Ibrahim; Antonio Marchetti; Keith Miller; J Han van Krieken; Soren Nielsen; Paul E Swanson; Clive R Taylor; Mogens Vyberg; Xiaoge Zhou; Emina E Torlakovic
Journal:  Appl Immunohistochem Mol Morphol       Date:  2017-01

Review 3.  Evolution of Quality Assurance for Clinical Immunohistochemistry in the Era of Precision Medicine - Part 2: Immunohistochemistry Test Performance Characteristics.

Authors:  Emina E Torlakovic; Carol C Cheung; Corrado D'Arrigo; Manfred Dietel; Glenn D Francis; C Blake Gilks; Jacqueline A Hall; Jason L Hornick; Merdol Ibrahim; Antonio Marchetti; Keith Miller; J Han van Krieken; Soren Nielsen; Paul E Swanson; Mogens Vyberg; Xiaoge Zhou; Clive R Taylor
Journal:  Appl Immunohistochem Mol Morphol       Date:  2017-02

4.  Evolution of Quality Assurance for Clinical Immunohistochemistry in the Era of Precision Medicine: Part 4: Tissue Tools for Quality Assurance in Immunohistochemistry.

Authors:  Carol C Cheung; Corrado D'Arrigo; Manfred Dietel; Glenn D Francis; Regan Fulton; C Blake Gilks; Jacqueline A Hall; Jason L Hornick; Merdol Ibrahim; Antonio Marchetti; Keith Miller; J Han van Krieken; Soren Nielsen; Paul E Swanson; Clive R Taylor; Mogens Vyberg; Xiaoge Zhou; Emina E Torlakovic
Journal:  Appl Immunohistochem Mol Morphol       Date:  2017-04

5.  Evolution of Quality Assurance for Clinical Immunohistochemistry in the Era of Precision Medicine. Part 3: Technical Validation of Immunohistochemistry (IHC) Assays in Clinical IHC Laboratories.

Authors:  Emina E Torlakovic; Carol C Cheung; Corrado D'Arrigo; Manfred Dietel; Glenn D Francis; C Blake Gilks; Jacqueline A Hall; Jason L Hornick; Merdol Ibrahim; Antonio Marchetti; Keith Miller; J Han van Krieken; Soren Nielsen; Paul E Swanson; Mogens Vyberg; Xiaoge Zhou; Clive R Taylor
Journal:  Appl Immunohistochem Mol Morphol       Date:  2017-03

Review 6.  Review of precision cancer medicine: Evolution of the treatment paradigm.

Authors:  Apostolia M Tsimberidou; Elena Fountzilas; Mina Nikanjam; Razelle Kurzrock
Journal:  Cancer Treat Rev       Date:  2020-03-31       Impact factor: 12.111

7.  PD-L1 Immunohistochemistry Comparability Study in Real-Life Clinical Samples: Results of Blueprint Phase 2 Project.

Authors:  Ming Sound Tsao; Keith M Kerr; Mark Kockx; Mary-Beth Beasley; Alain C Borczuk; Johan Botling; Lukas Bubendorf; Lucian Chirieac; Gang Chen; Teh-Ying Chou; Jin-Haeng Chung; Sanja Dacic; Sylvie Lantuejoul; Mari Mino-Kenudson; Andre L Moreira; Andrew G Nicholson; Masayuki Noguchi; Giuseppe Pelosi; Claudia Poleri; Prudence A Russell; Jennifer Sauter; Erik Thunnissen; Ignacio Wistuba; Hui Yu; Murry W Wynes; Melania Pintilie; Yasushi Yatabe; Fred R Hirsch
Journal:  J Thorac Oncol       Date:  2018-05-22       Impact factor: 15.609

8.  Canadian Association of Pathologists-Association canadienne des pathologistes National Standards Committee/Immunohistochemistry: best practice recommendations for standardization of immunohistochemistry tests.

Authors:  Emina Emilia Torlakovic; Robert Riddell; Diponkar Banerjee; Hala El-Zimaity; Dragana Pilavdzic; Peter Dawe; Anthony Magliocco; Penny Barnes; Richard Berendt; Donald Cook; Blake Gilks; Gaynor Williams; Bayardo Perez-Ordonez; Bret Wehrli; Paul E Swanson; Christopher N Otis; Søren Nielsen; Mogens Vyberg; Jagdish Butany
Journal:  Am J Clin Pathol       Date:  2010-03       Impact factor: 2.493

9.  PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project.

Authors:  Fred R Hirsch; Abigail McElhinny; Dave Stanforth; James Ranger-Moore; Malinka Jansson; Karina Kulangara; William Richardson; Penny Towne; Debra Hanks; Bharathi Vennapusa; Amita Mistry; Rasika Kalamegham; Steve Averbuch; James Novotny; Eric Rubin; Kenneth Emancipator; Ian McCaffery; J Andrew Williams; Jill Walker; John Longshore; Ming Sound Tsao; Keith M Kerr
Journal:  J Thorac Oncol       Date:  2016-11-29       Impact factor: 15.609

10.  Reproducibility of PD-L1 immunohistochemistry interpretation across various types of genitourinary and head/neck carcinomas, antibody clones, and tissue types.

Authors:  Chiyun Wang; Elan Hahn; Elzbieta Slodkowska; Antoine Eskander; Danny Enepekides; Kevin Higgins; Danny Vesprini; Stanley K Liu; Michelle R Downes; Bin Xu
Journal:  Hum Pathol       Date:  2018-08-01       Impact factor: 3.466
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.